



Health Canada Authorizes Emerald Health to begin Production of Cannabis Oil and to Expand Production Space

VICTORIA, BC, November 09, 2015 – Emerald Health Therapeutics Inc. (TSXV: EMH) ("Therapeutics") is pleased to announce that Emerald Health Botanicals Inc. ("Botanicals"), its wholly owned subsidiary, has received a Supplemental License from Health Canada authorizing Botanicals to produce cannabis oils and capsules. Health Canada concurrently approved two additional production rooms at Botanicals' production facility and renewed its medical cannabis production and sales license under the Marihuana for Medical Purposes Regulations for a period of one year. The two additional production rooms will significantly increase Botanicals' growing capacity and will be brought online effective immediately.

"We are excited by what the Supplemental License means to patients who would like to access their medicine in a variety of forms. We are uniquely positioned to provide medical cannabis to patients in oils and capsules, that can be properly dosed and assessed through clinical studies, given our teams extensive experience in drug development", stated Dr. Avtar Dhillon, Chairman of Therapeutics. "We are committed to providing a consistent, quality product and have acquired the equipment to begin production of cannabis oils immediately."

As Botanicals reviews its growth strategy it has, effective October 31, terminated its lease agreement on a facility in Victoria, BC that it was considering as a second cultivation facility. The Company is actively pursuing other options of expansion that would allow for more flexible space planning in a modular approach.

Emerald Health Therapeutics Inc.

Emerald Health Therapeutics wholly owns Emerald Health Botanicals, which holds licenses under the Marihuana for Medical Purposes Regulations to cultivate and sell medical cannabis, and to produce medical cannabis oil and capsules, in Canada.

ON BEHALF OF THE BOARD

"Dr. Bin Huang"
CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and sales of medical marijuana, anticipated revenues, projected size of market, quantities of future medical marijuana production, completion of production facilities and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, results of production and sale activities, the Company's historical experience with medical marijuana operations, uninsured risks, regulatory changes, availability of production facilities, timeliness of government approvals and the granting of permits and licenses, changes in prices, actual operating and financial performance of facilities, equipment and processes relative to specifications and expectations. Actual results may differ materially from those expressed or implied by such forward-looking statements.

For further information: Please contact Kam Thindal at 604-566-9233 or kam@htcapitalcorp.com.